Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release versus immediate-release flucytosine in adults with cryptococcal meningitis
PACTR202306577982404Phase 2Recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of flucytosine in cryptococcal meningitis (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Comparative bioavailability, Efficacy and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
flucytosine
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on PACTR202306577982404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202306577982404.